Ciclindole (; developmental code name WIN-27,147-2), also known as cyclindole (), is an antipsychotic of the tetrahydrocarbazolamine family with a tricyclic cyclized tryptamine structure that was never marketed.
It displaces spiperone binding in vitro and elevates dopamine levels in the striatum, indicating that it acts as a dopamine D<sub>2</sub> receptor antagonist. It also shows apparent affinity for the ñ<sub>1</sub>-adrenergic receptor, the serotonin S<sub>1</sub> receptor, and the serotonin S<sub>2</sub> receptor. However, its affinities for all of the preceding targets are weak, in the low micromolar range.
The related drug flucindole is about 5 to 10times more potent than ciclindole both in vitro and in vivo.